Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166438 | 0.86 | FGFR4 (0.59) | FGFR4FGFR1FGFR2FGFR3MAPK3 | |
| SCHEMBL17974143 | 0.82 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3TNK2 | |
| SCHEMBL23653249 | 0.74 | FGFR4 (0.43) | FGFR4FGFR1FGFR2FGFR3MAPK3 | |
| SCHEMBL16134080 | 0.73 | FGFR4 (0.74) | FGFR4 | |
| SCHEMBL24690431 | 0.71 | FGFR4 (0.51) | FGFR4LRRK2MAPK3PTK2 | |
| SCHEMBL22337302 | 0.68 | TNK2 (0.69) | TNK2MAPK7LRRK2PTK2 | |
| SCHEMBL15434041 | 0.68 | MAPK3 (0.47) | FGFR4FGFR1LRRK2MAPK3PTK2 | |
| SCHEMBL15946708 | 0.65 | CCNK (0.42) | LRRK2MAPK3PTK2 | |
| SCHEMBL16137332 | 0.65 | LRRK2 (0.47) | LRRK2MAPK3 | |
| SCHEMBL16134078 | 0.64 | SYK (0.44) | FGFR4LRRK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885FGFR1 1733/4885FGFR2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.